Sunovion Pharmaceuticals has launched Zetonna(ciclesonide)Nasal Aerosol,74 mcg once-daily,in the US,which is used to treat allergic rhinitis(AR),also known as hay fever or nasal allergies.
Zetonna is also used to treat symptoms associated with seasonal allergic rhinitis(SAR)and perennial allergic rhinitis(PAR)in adults and adolescents 12 years of age and older.
Zetonna is the third ciclesonide formulation marketed by Sunovion while the remaining two being Alvesco and Omnaris.
It is the only dry nasal aerosol approved by the US Food and Drug Administration(FDA)with once daily,one spray per nostril(37 mcg)dosing.
Sunovion Pharmaceuticals executive vice president and chief commercial officer Richard Russell said Zetonna joins Omnaris(ciclesonide)Nasal Spray as the newest addition in Sunovion's ciclesonide franchise.
''These treatments offer different experiences for patients,as OMNARIS is an aqueous,once-daily,two spray per nostril option for SAR patients 6 and older and PAR patients 12 and older,"Russell added.
"We are proud to be the only company to provide patients with the option of a dry aerosol or aqueous treatment,as well as a best-in-class co-pay program that allows qualified patients to pay as little as$17 a month for either ZETONNA or OMNARIS."
